The "Eight provinces and two districts" alliance will carry out the fourth batch of pharmaceutical collection, and the self -funded varieties must also be limited.

Non -medical insurance products are being included in the collection.

On July 6, Liaoning Provincial Pharmaceutical and Medical Consumption Purchasing Network issued an announcement saying that the "Eight provinces and two districts" provincial inter -provincial alliance will soon carry out the fourth batch of pharmaceutical collection.

Different from the 32 varieties passed on the Internet before, there are only 18 collected drugs finalized by the "Eight provinces and two districts" alliance, including 18 varieties such as shiitake mushroom polysaccharides, compound vitamin (3), all of which are injections or oral interpretation.

Of the 18 varieties, 13 are non -medical insurance, and 3 have entered the first batch of key monitoring directory.

The local collection policy has been implemented for 3 years. In addition to the hot -discovered dental implants, other collective varieties are basically selected in medical insurance. At present, the "Eight Provincial and Two Districts" provincial alliance not only collects self -cost medicine, but even directly includes a variety of key monitoring varieties that need to control the amount. It can be seen that Ji Cai has reached a new stage.

Non -medical insurance concentration, the self -funded variety must be limited to the price limit

In May 2021, the "Eight Provincial and Two Districts" alliance established by Heilongjiang, Shanxi, Liaoning, etc., promised to carry out two batches of drugs and medical consumables each year, and the provinces took turns lead and voluntarily participated.

At present, this alliance has purchased varieties including 55 drugs such as aminosptide injection, as well as consumables such as coronary vein dilation of ball pockets.

However, more than 70%of the varieties included in the "Eight Provincial and Two Districts" alliance this year are non -national medical insurance products with large market size.

Taking antibiotic sulfuric acid according to rice star as an example, this product was developed by Jimin's credibility. As early as 1999, it was certified by a national first -class drug. The market size reaches one billion yuan. But later, as the local area began to retreat, the category of replenishment, sulfuric acid Yitidi also completely bid farewell to medical insurance.

Another more common is Hydrochloric acid Divisp injection, which is mainly used to treat nerve and cerebrovascular diseases. At present, the sales of this product in the domestic market are mainly generic drugs. Manufacturers include China Resources Shuanghe, Yabao Pharmaceutical, Harbin Syntica Pharmaceutical and so on. In 2020, its market size reached 1.245 billion yuan.

In the previous national or local alliance collection, there have also been precedents for non -medical insurance varieties. For example, in January 2020, the second batch of leukin batch of albumin injection was not a variety of medical insurance reimbursement at the time. However, due to the large dosage and many manufacturers, it meets the collection conditions.

This time, the "eight provinces and two districts" alliance chose these non -medical insurance products, and may also want to press down the prices of these large varieties through the exchange.

The Jianzhi Bureau noticed that some areas have clearly begun to control the price of self -funded drugs. For example, in 2021, Shanghai has conducted a price verification twice and requires self -funded drugs to implement the lowest network price in Shanghai in Shanghai, otherwise it will be suspended. This type of verification is still the price linkage between different regions, and it does not require enterprises to reduce prices. The batch collection of non -medical insurance varieties of "eight provinces and two districts" opened a precedent in the country.

However, for enterprises, there is no restriction on medical insurance. Whether these products can really achieve "replacement" after the price reduction still need to draw a question mark.

Focusing on the selection of the monitoring, the directory effect is doubtful?

Another special point of the fourth batch of "eight provinces and two districts" is that the three national key monitoring products are included in the three national key monitoring products, which are included in the thymatic gland peptide, sodium phosphate, and front of front ground.

In 2019, the first batch of 20 national version of the key monitoring directory was released. These 20 varieties themselves are auxiliary medicines, and are the hardest hit areas for gold. After this directory was released, these varieties were kicked out of national medical insurance, and the sales of products were dived.

Taking thymptophyls of peptides as an example, this is an immune regulator, which is suitable for the immune function caused by radiotherapy and chemotherapy for patients with malignant tumors. According to Mine.com, in 2019, the sales of this product will still be more than 3 billion yuan, but by 2020, there will be only 1 billion yuan, and the market size shrinks 2/3.

Another sodium sodium sodium sodium glycosaccharide neurosonica was suspended by the former State Food and Drug Administration for sales, use, and imported by the former State Food and Drug Administration for "major quality and safety risks" in 2017. In 2019, after the conspiracy was included in the key monitoring, such products also gradually withdrawn from the market in the hospital. The market size dropped from approximately 3 billion yuan in 2018 to 700 million yuan in 2020.

The "key monitoring varieties" are all outside the medical insurance. It is reasonable to say that it is not involved in the collection, because this variety does not conform to the main principles of collecting and mining: occupying more medical insurance funds and a large amount of dosage.

It is very "common" to the national key monitoring varieties.

In fact, it is of positive significance to control the use and pricing of local key monitoring varieties. The Jianzhi Bureau noticed that although some varieties were "key monitoring" in some provinces, the dosage remained high. At the beginning of February this year, the Fujian Provincial Medical Insurance Bureau announced the third batch of key monitoring drugs in the province. Of the nine varieties, 7 were on the list for the second time, and there were three consecutive charts and three batches of directory.

Fujian is the birthplace of key monitoring. In accordance with the requirements of the local medical insurance bureau, Fujian's key monitoring directory implemented a dynamic adjustment strategy once every six months. The same medicine has been on the list repeatedly, obviously "monitoring", and insufficient strength.

However, the situation of the national key monitoring varieties is completely different from local monitoring, which has almost lost the market, and the significance of these varieties is not great.

- END -